That's a great question.
I would say that we can be optimistic and supportive of what we've been seeing in the last few years, obviously in part through the big challenges of COVID‑19, but this is an opportunity to, as we're doing now, build up the biomanufacturing sector in Canada through investments in Sanofi, in Moderna, in AstraZeneca, in other companies that are going to bring back to Canada lots of the biomanufacturing companies and expertise that we've unfortunately lost over the last decades.